Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 8/20 | 0.41 |
| ▸ | LAP3 | P28838 | 3/20 | 0.36 |
| ▸ | ANPEP | P15144 | 4/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166514 | 0.89 | CYP3A4 (0.43) | CCR1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL6165984 | 0.76 | CCR1 (0.33) | CCR1 | |
| SCHEMBL6675017 | 0.72 | CCR1 (0.61) | CCR1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL7591156 | 0.72 | CCR1 (0.61) | CCR1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL4066974 | 0.71 | CCR1 (0.49) | CCR1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL6168759 | 0.71 | CCR1 (0.31) | CCR1 | |
| SCHEMBL4058726 | 0.70 | CCR1 (0.50) | CCR1LAP3ANPEPRNPEPDNPEP | |
| SCHEMBL4064741 | 0.70 | CCR1 (0.50) | CCR1REN | |
| SCHEMBL6166224 | 0.70 | ADRA2A (0.32) | — | |
| SCHEMBL6169670 | 0.70 | CCR1 (0.61) | CCR1LAP3ANPEPRNPEPDNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498417-A1 | Heterocyclic amide derivatives | Pfizer Products Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004039375-A1 | METHODS OF USING CCR1 ANTAGONISTS AS IMMUNOMODULATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | PFIZER INC | 2004-05-06 | — | — | US | disclosed |
| US-6689886-B2 | TREATMENT OF INFLAMMATION AND OTHER IMMUNE DISORDERS | PFIZER INC. | 2004-02-10 | — | — | US | disclosed |
| US-20030204086-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2003-10-30 | — | — | US | disclosed |
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| EP-1252154-A1 | HETEROCYCLIC AMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2001057023-A1 | HETEROCYCLIC AMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204086-A1 | Novel heterocyclic amide derivatives | HAX1, ARG1, CXCR2 | CCR1 58/4885LAP3 2960/4885ANPEP 3196/4885 |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | CCR1, CCR3, CCRL2 | CCR1 1/4885LAP3 2885/4885ANPEP 4071/4885 |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | ARG1, IL4, ARG2 | CCR1 32/4885LAP3 2329/4885ANPEP 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.